Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Phase 1/2 Dose Escalation and Treatment Optimization Study Evaluating Safety, Tolerability, and Preliminary Efficacy of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET

NCT07873450 is registered in ClinicalTrials.gov with Full-Life Technologies UK Limited as lead sponsor.

NCT NCT07873450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07873450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Phase 1/2 Dose Escalation and Treatment Optimization Study Evaluating Safety, Tolerability, and Preliminary Efficacy of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
Lead sponsor
Full-Life Technologies UK Limited
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
June 30, 2030
Enrollment
208 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, colorectal cancer, head and neck cancer, nsclc, solid tumor